↓ Skip to main content

Dehydroepiandrosterone for systemic lupus erythematosus

Overview of attention for article published in Cochrane database of systematic reviews, October 2007
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)

Mentioned by

wikipedia
1 Wikipedia page

Readers on

mendeley
35 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dehydroepiandrosterone for systemic lupus erythematosus
Published in
Cochrane database of systematic reviews, October 2007
DOI 10.1002/14651858.cd005114.pub2
Pubmed ID
Authors

Crosbie, D, Black, C, McIntyre, L, Royle, P L, Thomas, S, Crosbie, David, Black, Corri, McIntyre, Linda, Royle, Pamela, Thomas, Sian

Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory, multisystem autoimmune condition. Dehydroepiandrosterone (DHEA) is a naturally occurring inactive steroid which may possess disease activity modifying properties as well as the ability to reduce flares and steroid requirements. To assess the effectiveness and safety of dehydroepiandrosterone compared to placebo in the treatment of people with systemic lupus erythematosus. We searched The Cochrane Library (Issue 2, 2006), MEDLINE, Pub Med, EMBASE, Science Citation Index and ISI Proceedings as well as searching web sites of Genelabs, FDA and EMEA. (Searches undertaken in June 2006 unless otherwise specified). We included randomised controlled trials of at least three months duration comparing DHEA to a placebo in people with SLE. Two review authors assessed quality and extracted data. From the seven RCTs identified (842 participants) to date there is 'gold' ranking evidence (www.cochranemsk.org) that DHEA: had little clinical effect on disease activity in those with mild/moderate disease (measured by SLEDAI or SLAM) but one study demonstrated evidence of stabilisation or improvement in 8.3% more patients than those treated with placebo; had a modest but clinically significant improvement in health related quality of life measured by Patient Global Assessment, estimated as 11.5% (11.5 mm on a 100 mm scale) by meta-analysis; resulted in a greater number of patients experiencing adverse events, particularly androgenic effects such as acne where patients risk was doubled when compared to placebo (RR 2.2; 95% CI 1.65 to 2.83) Studying effectiveness of DHEA for SLE is difficult, reflecting the problems of studying any treatment for a disease as complex as SLE. From the seven RCTs to date, there was evidence that DHEA had a modest but clinically significant impact on health related quality of life in the short term. Impact on disease activity was inconsistent, with DHEA showing no benefit over placebo in terms of change in SLEDAI in all but one of the 6 studies reporting this outcome. Long term outcomes and safety remain unstudied.

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 35 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 23%
Student > Master 7 20%
Student > Ph. D. Student 7 20%
Student > Doctoral Student 3 9%
Other 2 6%
Other 8 23%
Readers by discipline Count As %
Medicine and Dentistry 18 51%
Unspecified 6 17%
Psychology 5 14%
Nursing and Health Professions 3 9%
Agricultural and Biological Sciences 2 6%
Other 1 3%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 July 2017.
All research outputs
#3,214,806
of 11,477,928 outputs
Outputs from Cochrane database of systematic reviews
#6,297
of 9,122 outputs
Outputs of similar age
#74,823
of 252,439 outputs
Outputs of similar age from Cochrane database of systematic reviews
#182
of 244 outputs
Altmetric has tracked 11,477,928 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 9,122 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.7. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,439 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 244 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.